AstraZeneca PLC
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
AZN | IL
Overview
Corporate Details
- ISIN(s):
- GB0009895292 (+925 more)
- LEI:
- PY6ZZQWO2IZFZC3IOL08
- Country:
- United Kingdom
- Address:
- 1 FRANCIS CRICK AVENUE, CB2 0AA CAMBRIDGE
- Website:
- https://www.astrazeneca.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The company's primary therapeutic areas include Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Diseases. AstraZeneca develops, manufactures, and sells pharmaceutical and biotechnology products aimed at addressing complex health challenges for millions of patients worldwide. The firm maintains a significant research and development pipeline to create innovative treatments and transform healthcare through scientific advancement.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-26 08:25 |
Regulatory Filings
Imfinzi approved in US for early gastric cancer
|
English | 33.0 KB | ||
| 2025-11-24 08:25 |
Regulatory Filings
AstraZeneca manufacturing investment in Maryland
|
English | 11.5 KB | ||
| 2025-11-20 08:25 |
Regulatory Filings
Koselugo (selumetinib) approved in the US
|
English | 22.0 KB | ||
| 2025-11-17 16:10 |
Major Shareholding Notification
Holding(s) in Company
|
English | 24.7 KB | ||
| 2025-11-14 12:10 |
Director's Dealing
Director/PDMR Shareholding
|
English | 21.7 KB | ||
| 2025-11-10 16:10 |
Director's Dealing
Director/PDMR Shareholding
|
English | 18.9 KB | ||
| 2025-11-06 08:20 |
Earnings Release
9M and Q3 2025 results
|
English | 865.0 KB | ||
| 2025-11-06 08:00 |
Earnings Release
|
English | 1.4 MB | ||
| 2025-11-03 17:10 |
AGM Information
Result of General Meeting
|
English | 16.9 KB | ||
| 2025-11-03 17:06 |
AGM Information
Special Resolution Approved at General Meeting
|
English | 78.4 KB | ||
| 2025-11-03 16:59 |
Registration Form
Articles of Association approved at General Meeting
|
English | 569.8 KB | ||
| 2025-11-03 16:10 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 8.8 KB | ||
| 2025-10-28 08:05 |
Board/Management Information
Director Declaration
|
English | 7.4 KB | ||
| 2025-10-22 08:00 |
Regulatory Filings
Tezspire Approved in EU for CRSwNP
|
English | 29.9 KB | ||
| 2025-10-20 08:05 |
Regulatory Filings
US FDA Approves Tezspire in CRSwNP
|
English | 36.7 KB |
Automate Your Workflow. Get a real-time feed of all AstraZeneca PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AstraZeneca PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AstraZeneca PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-13 | Philip Broadley | Other | Buy | 980 | 99,665.12 EUR |
| 2024-03-08 | Pascal Soriot | Other | Other | 105,238 | N/A |
| 2024-03-05 | Pascal Soriot | Other | Other | 17,702 | N/A |
| 2024-03-04 | Pascal Soriot | Other | Other | 109,872 | 11,076,196.32 EUR |
| 2024-03-04 | Aradhana Sarin | Other | Other | 59,125 | 5,960,391.25 EUR |
| 2023-12-12 | Anna Manz | Other | Buy | 487 | 49,623.16 EUR |
| 2023-11-22 | Michel Demare | Other | Buy | 1,000 | 101,700.00 EUR |
| 2023-11-21 | Michel Demare | Other | Buy | 1,000 | 101,052.24 EUR |
| 2023-04-28 | Michel Demare | Other | Buy | 2,000 | 234,020.00 EUR |
| 2023-03-23 | Pascal Soriot | Other | Other | 138,093 | N/A |
Peer Companies
